NPC1L1 and sarcopenia: For the NPC1L1 inhibition, additional analysis using an LD threshold of r2 < 0.3 to increase the number of SNPs as instruments revealed a potential causal association with a lower risk of CHD (Supplementary Table S5), and no causal association with any of the three sarcopenia-related traits (Supplementary Table S6).